Theravance, Astellas get European nod for Vibativ; Abbott lays off 160 in diagnostics restructuring;

@FiercePharma: FDA expects another foreign-drug safety crisis a la heparin ... if it doesn't get more enforcement powers. Story | Follow @FiercePharma

> European regulators approved Theravance and Astellas Pharma's antibiotic Vibativ to treat pneumonia suspected to be caused by MRSA. Release

> Abbott Laboratories ($ABT) has laid off 160 employees as part of ongoing restructuring within its diagnostics division. News

> Eli Lilly ($LLY) India's CEO says the company will rely on its own original drugs to grow on the subcontinent, rather than buying in "a slew of branded generics." Report

> Eli Lilly is expanding its social media efforts with a YouTube channel and a new Facebook page. Item

> Novartis ($NVS) study finds Galvus safe and effective in diabetics with severely impaired kidney function. Story

> Spencer Pharmaceutical officials said Al-Dorra/Hail First Pharma's buyout offer should be rejected; the bid has not been changed since June. Spencer release

> Women who can buy longer-term supplies of birth-control pills are more likely to stick with them. Article

Biotech News

@FierceBiotech: FDA approves test to determine chances of ovarian cancer. Piece | Follow @FierceBiotech

@JohnCFierce: Soligenix will now look at cost containment measures now that orBec Ph3 is a bust. Here's the PR: Item | Follow @JohnCFierce

@RyanMFierce: Neat. Computer-based therapy for anxiety may be as effective as seeing a therapist or taking drugs. Brown U.'s release: Release | Follow @RyanMFierce

@MaureenFierce:  Bionor HIV vaccine lowers viral load, ART need. Report | Follow @MaureenFierce

> Soligenix slams the door on disappointing orBec Ph3. Item 

Vaccines News

> FDA lifts clinical hold on RXi's breast cancer vaccine. News

> Bionor HIV vaccine lowers viral load, ART need. Story 

> Researchers find weakness in hep C virus. Report

> Medicago unveils new NC manufacturing plant. Article 

> Study: For HPV, two shots may be enough. News

Manufacturing News

> Daiichi riding GMP rollercoaster with FDA. Report

> Teva gets close-out letter over Jerusalem plant. Story 

> Competition forcing marriage of iPads, ops data for execs. Article

> Seattle the exception in hosting medical marijuana dispensaries. Report 

> Catalent expansions show close pharma-biz tracking. News  

And Finally... Harvard releases its own version of the government's "healthy plate" eating advice. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.